• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 12:23:41 PM ET
    $ALXN
    Major Pharmaceuticals
    Health Care
    Get the next $ALXN alert in real time by email
    SC 13G/A 1 alxn13gadec20.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 23) ALEXION PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 015351109 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is filed: [x] Rule 13d - 1(b) Rule 13d - 1(c) Rule 13d - 1(d) 1. Name of Reporting Person T. ROWE PRICE ASSOCIATES, INC. 52-0556948 2. Check the Appropriate Box if a Member of a Group NOT APPLICABLE 3. SEC Use Only 4. Citizenship or Place of Organization Maryland Number of Shares Beneficially Owned by Each Reporting Person With 5. Sole Voting Power* 425,078 6. Shared Voting Power* 0 7. Sole Dispositive Power* 1,536,173 8. Shared Dispositive Power 0 9. Aggregate Amount Beneficially Owned by Each Reporting Person 1,536,173 10. Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares NOT APPLICABLE 11. Percent of Class Represented by Amount in Row 9 0.7% 12. Type of Reporting Person IA *Any shares reported in Items 5 and 6 are also reported in Item 7. Item 1(a) Name of Issuer: ALEXION PHARMACEUTICALS, INC. Item 1(b) Address of Issuer's Principal Executive Offices: 121 SEAPORT BOULEVARD, BOSTON, MASSACHUSETTS 02210 Item 2(a) Name of Person(s) Filing: (1) T. ROWE PRICE ASSOCIATES, INC. ("Price Associates") Item 2(b) Address of Principal Business Office: 100 E. Pratt Street, Baltimore, MD 21202 Item 2(c) Citizenship or Place of Organization: (1) Maryland Item 2(d) Title of Class of Securities: COMMON STOCK Item 2(e) Cusip Number: 015351109 Item 3: The person filing this Schedule 13G is an: X Investment Adviser registered under Section 203 of the Investment Advisers Act of 1940 Item 4: Reference is made to Items 5-11 on the preceding pages of this Schedule 13G. Item 5: Ownership of Five Percent or Less of a Class This statement is being filed to report the fact that, as of the date of this report, the reporting person(s) has (have) ceased to be the beneficial owner of more than five percent of the class of securities. Item 6: Ownership of More than Five Percent on Behalf of Another Person (1) Price Associates does not serve as custodian of the assets of any of its clients; accordingly, in each instance only the client or the client's custodian or trustee bank has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. The ultimate power to direct the receipt of dividends paid with respect to, and the proceeds from the sale of, such securities, is vested in the individual and institutional clients which Price Associates serves as investment adviser. Any and all discretionary authority which has been delegated to Price Associates may be revoked in whole or in part at any time. Except as may be indicated if this is a joint filing with one of the registered investment companies sponsored by Price Associates which it also serves as investment adviser ("T. Rowe Price Funds"), not more than 5% of the class of such securities is owned by any one client subject to the investment advice of Price Associates. (2) With respect to securities owned by any one of the T. Rowe Price Funds, only the custodian for each of such Funds, has the right to receive dividends paid with respect to, and proceeds from the sale of, such securities. No other person is known to have such right, except that the shareholders of each such Fund participate proportionately in any dividends and distributions so paid. Item 7: Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. Not Applicable Item 8: Identification and Classification of Members of the Group Not Applicable Item 9: Notice of Dissolution of Group Not Applicable Item 10: Certification By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied. Signature. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. T. ROWE PRICE ASSOCIATES, INC. Date: February 16, 2021 Signature: /s/ David Oestreicher Name & Title: David Oestreicher, Executive Vice President 12/31/2020
    Get the next $ALXN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALXN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALXN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: COUGHLIN CHRISTOPHER J returned 42,347 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:54:11 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: FRIEDMAN PAUL A returned 12,840 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:51:08 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4: SARIN ARADHANA returned 120,253 units of Common Stock to the company, closing all direct ownership in the company

      4 - ALEXION PHARMACEUTICALS, INC. (0000899866) (Issuer)

      7/23/21 4:52:30 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    SEC Filings

    See more
    • SEC Form 15-12G filed by Alexion Pharmaceuticals, Inc.

      15-12G - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      8/2/21 9:02:07 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:08 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Alexion Pharmaceuticals, Inc.

      EFFECT - ALEXION PHARMACEUTICALS, INC. (0000899866) (Filer)

      7/26/21 12:15:53 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/16/21 12:23:41 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/12/21 6:51:47 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ALEXION PHARMACEUTICALS, INC. (0000899866) (Subject)

      2/10/21 10:30:29 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alexion Pharma upgraded by Oppenheimer with a new price target

      Oppenheimer upgraded Alexion Pharma from Perform to Outperform and set a new price target of $205.00

      5/5/21 6:41:15 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Credit Suisse resumed coverage on Alexion Pharma with a new price target

      Credit Suisse resumed coverage of Alexion Pharma with a rating of Neutral and set a new price target of $190.00

      4/26/21 8:53:18 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Alexion Pharma downgraded by SVB Leerink

      SVB Leerink downgraded Alexion Pharma from Outperform to Mkt Perform

      3/23/21 7:28:52 AM ET
      $ALXN
      Major Pharmaceuticals
      Health Care

    $ALXN
    Leadership Updates

    Live Leadership Updates

    See more

    $ALXN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Dicerna Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      LEXINGTON, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Compensation Committee of the Company's Board of Directors approved inducement grants of stock options to purchase a total of 30,575 shares of common stock and 8,750 restricted stock units (“RSUs”) to be distributed among six new employees with a grant date of Dec. 1, 2020 (the “Inducement Grants”). The stock options approved under the Inducement Grants were issued pursuant to Dicerna’s 2016 Inducement Plan and have an exercise price per share equal to $24.76,

      12/1/20 4:30:00 PM ET
      $LLY
      $DRNA
      $NVO
      $ALXN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Moderna Set to Join S&P 500

      NEW YORK, July 15, 2021 /PRNewswire/ -- Moderna Inc. (NASD:MRNA) will replace Alexion Pharmaceuticals Inc. (NASD:ALXN) in the S&P 500 effective prior to the opening of trading on Wednesday, July 21. AstraZeneca Plc (LSE:AZN; NASD:AZN) is acquiring Alexion Pharmaceuticals in a deal expected to be completed soon pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector July 21, 2021 S&P 500 Addition Moderna MRNA Health Care S&P 500 Deletion Alexion Pharmaceuticals ALXN Health Care For more information about S&P Dow Jones Indices, please

      7/15/21 7:01:00 PM ET
      $SPGI
      $ALXN
      $AZN
      $MRNA
      Finance: Consumer Services
      Finance
      Major Pharmaceuticals
      Health Care
    • Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

      – Study met primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score at Week 26 – – ULTOMIRIS demonstrated compelling efficacy as early as Week 1, sustained for 52 weeks – Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS® (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met, with high statistical significance, its primary endpoint of change from baseline in the Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) total score, a patient-reported assessment, at Week 26, and for the s

      7/15/21 4:05:00 PM ET
      $ALXN
      Major Pharmaceuticals
      Health Care
    • Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

      NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced that Honeywell International Inc. (NASDAQ:HON), will become a component of the NASDAQ-100 Index® (NASDAQ:NDX), the NASDAQ-100 Equal Weighted Index (NASDAQ:NDXE) and the NASDAQ-100 Ex-Technology Index (NASDAQ:NDXX) prior to market open on Wednesday, July 21, 2021. Honeywell International Inc. will replace Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the NASDAQ-100 Index®, the NASDAQ-100 Equal Weighted Index and the NASDAQ-100 Ex-Technology Index. For more information about the company, go to https://www.honeywell.com/ . About Nasdaq Nasdaq (NASDAQ:NDAQ) is a global technology company serving the capital ma

      7/14/21 8:00:00 PM ET
      $ALXN
      $NDAQ
      $HON
      Major Pharmaceuticals
      Health Care
      Investment Bankers/Brokers/Service
      Finance